Latest Articles
-
Merck’s Leadership In HPV Vaccines Market
Merck’s (NYSE:MRK) Gardasil is the leader in the human papillomavirus (HPV) vaccines market. HPV is a group of more than 200 related viruses, of which several are spread through direct sexual contact. HPV can cause cervical, anal, orophary...
-
How Important Is Keytruda For Merck?
Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and melanoma among others. It has become the most...
-
Will Merck’s #1 Therapeutic Area With $10 Billion In Revenue Grow?
Merck’s (NYSE:MRK) anti-infectious drugs business is the company’s largest therapeutic area and it will likely decline in low-single-digits from about $10.9 billion in 2018 to $10.4 billion in 2021, according to Trefis estimates. Thi...
-
How Much Can Merck’s Oncology Drugs Revenue Grow Over The Next Three Years?
Merck’s (NYSE:MRK) oncology drugs’ revenue could grow at a CAGR of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021, according to Trefis estimates. This growth will likely be led by higher sales of Keytruda, as well as high...
-
Merck’s Q1 Earnings Beat Led By Keytruda, And The Momentum Could Continue In The Near Term
Merck (NYSE:MRK) recently reported its Q1 2019 results, which were above our estimates. This note details the company’s Q1 performance, and Trefis’ forecasts for the full year 2019. You can view our interactive dashboard analysis ~ How Did Merck...
-
Merck’s Q1 Earnings Growth Will Likely Be Led By Higher Keytruda Sales
Merck (NYSE:MRK) is expected to publish its Q1 2019 results on April 30. This note details Trefis’ forecasts for Merck, as well as some of the key trends we will be watching when the company reports earnings. You can view our interactive dashboar...
-
How Much Can Merck’s Share Price Grow If Keytruda Gets 10% Share Of Oncology Drug Market?
Merck’s (NYSE:MRK) Keytruda has been on a strong run with sales exceeding $7 billion in 2018. This can be attributed to its superior benefits in lung cancer, and various regulatory approvals for multiple indications. While the drug’s ...
-
Merck’s Q4 Earnings And What Lies Ahead For The Company In 2019
Merck (NYSE:MRK) recently reported its Q4 2018 earnings, which were slightly below our estimates. The company’s top line and bottom line grew in mid-single-digits in Q4, led by a continued ramp up in Keytruda, and Gardasil sales. Looking fo...
-
Expect Keytruda & Gardasil To Drive Merck’s Q4 Earnings Growth
Merck (NYSE:MRK) is set to report its Q4 2018 earnings on February 1, and we expect the company to post mid-single-digit top line growth and low double-digits earnings growth. This can be attributed to the continued growth in the company’s ...
-
A Look At Merck’s Late Stage Pharmaceuticals Pipeline
Merck (NYSE:MRK) has a strong late stage pharmaceuticals pipeline, and it could be worth as much as $13 billion, or over 6% of its current market value, according to our estimates. Several drugs in the pipeline are capable of generating more than...
-
Keytruda And Gardasil Will Likely Continue To Drive Merck’s Earnings Growth
Merck (NYSE:MRK) continues to see steady top line growth, primarily led by Keytruda and Gardasil sales. The company’s Q3 results were more or less in line with our estimates, led by a strong growth in these two drugs. Looking forward, we co...
-
Here’s What Will Drive Merck’s Near Term Revenue Growth
Merck (NYSE:MRK) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary & Metabolism, Respiratory, Contraceptives drugs, along with its Mature Drugs & Other Segments. Anti-Infective and Mature Drugs & Oth...
-
What Will Drive Merck’s Near Term Growth
Merck (NYSE:MRK) has seen strong growth in its Oncology drug Keytruda, along with Vaccine Gardasil in the recent quarters. The company’s Q2 results topped street estimates, led by a strong growth in these two drugs. We continue to believe t...
-
A Ramp Up In Keytruda Sales Will Likely Drive Merck’s Q2 Earnings Growth
Merck (NYSE:MRK) is set to report its Q2 2018 earnings on July 27, and we expect the company to post steady growth, primarily led by its Oncology drug Keytruda. Among other segments, Anti-Infectives will likely remain sluggish, due to competitive...
-
Merck’s Alimentary & Metabolism Drug Sales Have Likely Peaked
Merck’s (NYSE:MRK) Alimentary & Metabolism drugs account for around 10% of the company’s value, according to our estimates. The key drugs in this segment are Januvia and Janumet. We don’t expect any significant growth for bo...
